|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.910 HKD | +0.88% |
|
+6.14% | +11.81% |
| 06:28pm | Sino Biopharmaceutical buys drugmaker Hangzhou Hygieia Biomedical for up to $172 million | RE |
| 05:48pm | Sino Biopharmaceutical announces acquisition of 100% equity interest in Hygieia | RE |
| Capitalization | 110B 122B 15.71B 13.45B 12.51B 11.66B 21.79B 1,416B 23.37B 144B 56.64B 677B 58.9B 57.69B 2,483B | P/E ratio 2025 * |
24.6x | P/E ratio 2026 * | 23.5x |
|---|---|---|---|---|---|
| Enterprise value | 103B 116B 14.84B 12.71B 11.82B 11.02B 20.58B 1,337B 22.08B 136B 53.5B 640B 55.64B 54.5B 2,346B | EV / Sales 2025 * |
3.13x | EV / Sales 2026 * | 2.7x |
| Free-Float |
51.86% | Yield 2025 * |
1.36% | Yield 2026 * | 1.4% |
| 1 day | +0.88% | ||
| 1 week | +6.14% | ||
| Current month | +11.81% | ||
| 1 month | +1.62% | ||
| 3 months | -11.41% | ||
| 6 months | +13.84% | ||
| Current year | +11.81% |
| 1 week | 6.52 |  | 7.17 |
| 1 month | 6.13 | | 7.17 |
| Current year | 6.18 | | 7.17 |
| 1 year | 2.67 | | 9.12 |
| 3 years | 2.29 | | 9.12 |
| 5 years | 2.29 | | 9.69 |
| 10 years | 2.05 | | 11.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 30 | 28/07/2022 |
Chun Ling Li
DFI | Director of Finance/CFO | 55 | 01/01/1996 |
Hsin Tse
IRC | Investor Relations Contact | 56 | 25/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping Tse
CHM | Chairman | 74 | 02/02/2000 |
Hsin Tse
BRD | Director/Board Member | 56 | 01/08/1995 |
| Director/Board Member | 61 | 10/04/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 2.4% | 0 M€ | |
| -3.45% | 0.82% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.88% | +6.14% | +142.46% | +43.66% | 15.71B | |
| +1.64% | +3.79% | +35.14% | +201.01% | 968B | |
| +2.61% | +2.65% | +47.63% | +20.53% | 505B | |
| -0.02% | -0.06% | +25.62% | +44.55% | 389B | |
| -0.92% | +4.30% | +28.16% | +17.49% | 367B | |
| -0.77% | +4.63% | +29.40% | +22.33% | 295B | |
| -1.21% | +1.63% | +10.02% | -2.31% | 271B | |
| -0.18% | +4.74% | +25.17% | +35.09% | 274B | |
| +1.50% | +11.16% | -37.13% | -15.63% | 263B | |
| -0.17% | +1.50% | +24.14% | +20.16% | 175B | |
| Average | +0.04% | +3.97% | +33.06% | +38.69% | 352.39B | |
| Weighted average by Cap. | +0.04% | +3.72% | +26.50% | +69.35% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.01B 36.91B 4.73B 4.05B 3.77B 3.51B 6.57B 427B 7.04B 43.43B 17.07B 204B 17.75B 17.39B 748B | 36.04B 40.3B 5.17B 4.43B 4.12B 3.84B 7.17B 466B 7.69B 47.41B 18.64B 223B 19.38B 18.99B 817B |
| Net income | 4.73B 5.29B 679M 581M 540M 504M 941M 61.16B 1.01B 6.22B 2.45B 29.26B 2.54B 2.49B 107B | 4.71B 5.27B 676M 579M 538M 502M 937M 60.89B 1.01B 6.2B 2.44B 29.13B 2.53B 2.48B 107B |
| Net Debt | -6.06B -6.78B -869M -744M -692M -645M -1.21B -78.33B -1.29B -7.97B -3.13B -37.47B -3.26B -3.19B -137B | -12.1B -13.53B -1.74B -1.49B -1.38B -1.29B -2.41B -156B -2.58B -15.92B -6.26B -74.82B -6.51B -6.37B -274B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 6.910 $ | +0.88% | 130,333,080 |
| 12/01/26 | 6.850 $ | +0.29% | 75,463,750 |
| 09/01/26 | 6.830 $ | +0.74% | 93,024,440 |
| 08/01/26 | 6.780 $ | -0.73% | 56,568,220 |
| 07/01/26 | 6.830 $ | +3.80% | 119,309,400 |
Delayed Quote Hong Kong S.E., January 13, 2026 at 04:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1177 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition